Arcus Biosciences, Inc. Research and Development Expense
Arcus Biosciences, Inc. (RCUS) reported Research and Development Expense of $113.00 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-05
- Arcus Biosciences, Inc. research and development expense for the quarter ending 2026-06-30 was $113.00M, a 18.71% decline year-over-year.
- Arcus Biosciences, Inc. research and development expense for the quarter ending 2026-03-31 was $122.00M, a 0.00% change year-over-year.
- Arcus Biosciences, Inc. research and development expense for the quarter ending 2025-12-31 was $121.00M, a 19.80% increase year-over-year.
- Arcus Biosciences, Inc. research and development expense for the quarter ending 2025-09-30 was $141.00M, a 14.63% increase year-over-year.
- Arcus Biosciences, Inc. research and development expense for fiscal 2025 was $523.00M, a 16.74% increase from fiscal 2024.
- Arcus Biosciences, Inc. research and development expense for fiscal 2024 was $448.00M, a 31.76% increase from fiscal 2023.
- Arcus Biosciences, Inc. research and development expense for fiscal 2023 was $340.00M, a 18.06% increase from fiscal 2022.
- Arcus Biosciences, Inc. research and development expense for fiscal 2022 was $288.00M, a 12.06% increase from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 3 month as first filed | Research and Development Expense 6 month | Research and Development Expense 6 month as first filed | Research and Development Expense 9 month | Research and Development Expense 9 month as first filed | Research and Development Expense 12 month | Research and Development Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $113.00M 10-Q · filed 2026-08-05 | $235.00M 10-Q · filed 2026-08-05 | $356.00M derived: sum of 3 quarters · filed 2026-08-05 | $497.00M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2026-03-31 | $122.00M 10-Q · filed 2026-05-05 | $243.00M derived: sum of 2 quarters · filed 2026-05-05 | $384.00M derived: sum of 3 quarters · filed 2026-05-05 | $523.00M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-12-31 | $121.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $262.00M derived: sum of 2 quarters · filed 2026-02-25 | $401.00M derived: sum of 3 quarters · filed 2026-08-05 | $523.00M 10-K · filed 2026-02-25 | ||||
| 2025-09-30 | $141.00M 10-Q · filed 2025-10-28 | $280.00M derived: sum of 2 quarters · filed 2026-08-05 | $402.00M 10-Q · filed 2025-10-28 | $503.00M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-06-30 | $139.00M 10-Q · filed 2026-08-05 | $261.00M 10-Q · filed 2026-08-05 | $362.00M derived: sum of 3 quarters · filed 2026-08-05 | $485.00M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-03-31 | $122.00M 10-Q · filed 2026-05-05 | $223.00M derived: sum of 2 quarters · filed 2026-05-05 | $346.00M derived: sum of 3 quarters · filed 2026-05-05 | $461.00M derived: sum of 4 quarters · filed 2026-05-05 | ||||
| 2024-12-31 | $101.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $224.00M derived: sum of 2 quarters · filed 2026-02-25 | $339.00M derived: sum of 3 quarters · filed 2026-02-25 | $448.00M 10-K · filed 2026-02-25 | ||||
| 2024-09-30 | $123.00M 10-Q · filed 2025-10-28 | $238.00M derived: sum of 2 quarters · filed 2025-10-28 | $347.00M 10-Q · filed 2025-10-28 | $440.00M derived: sum of 4 quarters · filed 2026-02-25 | ||||
| 2024-06-30 | $115.00M 10-Q · filed 2025-08-06 | $224.00M 10-Q · filed 2025-08-06 | $317.00M derived: sum of 3 quarters · filed 2026-02-25 | $399.00M derived: sum of 4 quarters · filed 2026-02-25 | ||||
| 2024-03-31 | $109.00M 10-Q · filed 2025-05-06 | $202.00M derived: sum of 2 quarters · filed 2026-02-25 | $284.00M derived: sum of 3 quarters · filed 2026-02-25 | $368.00M derived: sum of 4 quarters · filed 2026-02-25 | ||||
| 2023-12-31 | $93.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $175.00M derived: sum of 2 quarters · filed 2026-02-25 | $259.00M derived: sum of 3 quarters · filed 2026-02-25 | $340.00M 10-K · filed 2026-02-25 | ||||
| 2023-09-30 | $82.00M 10-Q · filed 2024-11-06 | $166.00M derived: sum of 2 quarters · filed 2024-11-06 | $247.00M 10-Q · filed 2024-11-06 | $327.00M derived: sum of 4 quarters · filed 2025-02-25 | ||||
| 2023-06-30 | $84.00M 10-Q · filed 2024-08-08 | $165.00M 10-Q · filed 2024-08-08 | $245.00M derived: sum of 3 quarters · filed 2025-02-25 | $322.00M derived: sum of 4 quarters · filed 2025-02-25 | ||||
| 2023-03-31 | $81.00M 10-Q · filed 2024-05-08 | $161.00M derived: sum of 2 quarters · filed 2025-02-25 | $238.00M derived: sum of 3 quarters · filed 2025-02-25 | $308.00M derived: sum of 4 quarters · filed 2025-02-25 | ||||
| 2022-12-31 | $80.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | $157.00M derived: sum of 2 quarters · filed 2025-02-25 | $227.00M derived: sum of 3 quarters · filed 2025-02-25 | $288.00M 10-K · filed 2025-02-25 | ||||
| 2022-09-30 | $77.00M 10-Q · filed 2023-11-07 | $76.68M 10-Q · filed 2022-11-02 | $147.00M derived: sum of 2 quarters · filed 2023-11-07 | $208.00M 10-Q · filed 2023-11-07 | $207.80M 10-Q · filed 2022-11-02 | $258.59M derived: sum of 4 quarters · filed 2024-02-21 | ||
| 2022-06-30 | $70.00M 10-Q · filed 2023-08-07 | $69.91M 10-Q · filed 2022-08-03 | $131.00M 10-Q · filed 2023-08-07 | $131.12M 10-Q · filed 2022-08-03 | $181.59M derived: sum of 3 quarters · filed 2024-02-21 | $252.84M derived: sum of 4 quarters · filed 2024-02-21 | ||
| 2022-03-31 | $61.00M 10-Q · filed 2023-05-09 | $61.21M 10-Q · filed 2022-05-09 | $111.59M derived: sum of 2 quarters · filed 2024-02-21 | $182.84M derived: sum of 3 quarters · filed 2024-02-21 | $251.61M derived: sum of 4 quarters · filed 2024-02-21 | |||
| 2021-12-31 | $50.59M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-21 | $121.84M derived: sum of 2 quarters · filed 2024-02-21 | $190.61M derived: sum of 3 quarters · filed 2024-02-21 | $257.00M 10-K · filed 2024-02-21 | $256.35M 10-K · filed 2022-02-23 | |||
| 2021-09-30 | $71.25M 10-Q · filed 2022-11-02 | $140.03M derived: sum of 2 quarters · filed 2022-11-02 | $206.41M 10-Q · filed 2022-11-02 | $254.78M derived: sum of 4 quarters · filed 2023-02-28 | ||||
| 2021-06-30 | $68.77M 10-Q · filed 2022-08-03 | $135.16M 10-Q · filed 2022-08-03 | $183.52M derived: sum of 3 quarters · filed 2023-02-28 | $235.32M derived: sum of 4 quarters · filed 2023-02-28 | ||||
| 2021-03-31 | $66.39M 10-Q · filed 2022-05-09 | $114.75M derived: sum of 2 quarters · filed 2023-02-28 | $166.55M derived: sum of 3 quarters · filed 2023-02-28 | $202.25M derived: sum of 4 quarters · filed 2023-02-28 | ||||
| 2020-12-31 | $48.36M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $100.17M derived: sum of 2 quarters · filed 2023-02-28 | $135.86M derived: sum of 3 quarters · filed 2023-02-28 | $159.00M 10-K · filed 2023-02-28 | $159.35M 10-K · filed 2021-02-25 | |||
| 2020-09-30 | $51.80M 10-Q · filed 2021-11-08 | $87.49M derived: sum of 2 quarters · filed 2021-11-08 | $110.64M 10-Q · filed 2021-11-08 | $131.32M derived: sum of 4 quarters · filed 2022-02-23 | ||||
| 2020-06-30 | $35.69M 10-Q · filed 2021-08-05 | $58.84M 10-Q · filed 2021-08-05 | $79.52M derived: sum of 3 quarters · filed 2022-02-23 | $96.76M derived: sum of 4 quarters · filed 2022-02-23 | ||||
| 2020-03-31 | $23.14M 10-Q · filed 2021-05-05 | $43.83M derived: sum of 2 quarters · filed 2022-02-23 | $61.07M derived: sum of 3 quarters · filed 2022-02-23 | $86.07M derived: sum of 4 quarters · filed 2022-02-23 | ||||
| 2019-12-31 | $20.69M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-23 | $37.93M derived: sum of 2 quarters · filed 2022-02-23 | $62.93M derived: sum of 3 quarters · filed 2022-02-23 | $78.48M 10-K · filed 2022-02-23 | ||||
| 2019-09-30 | $17.24M 10-Q · filed 2020-11-05 | $42.24M derived: sum of 2 quarters · filed 2020-11-05 | $57.80M 10-Q · filed 2020-11-05 | $69.23M derived: sum of 4 quarters · filed 2021-02-25 | ||||
| 2019-06-30 | $25.00M 10-Q · filed 2020-08-06 | $40.55M 10-Q · filed 2020-08-06 | $51.99M derived: sum of 3 quarters · filed 2021-02-25 | $64.85M derived: sum of 4 quarters · filed 2021-02-25 | ||||
| 2019-03-31 | $15.55M 10-Q · filed 2020-05-05 | $26.99M derived: sum of 2 quarters · filed 2021-02-25 | $39.85M derived: sum of 3 quarters · filed 2021-02-25 | $53.55M derived: sum of 4 quarters · filed 2021-02-25 | ||||
| 2018-12-31 | $11.44M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $24.30M derived: sum of 2 quarters · filed 2021-02-25 | $37.99M derived: sum of 3 quarters · filed 2021-02-25 | $49.65M 10-K · filed 2021-02-25 | ||||
| 2018-09-30 | $12.86M 10-Q · filed 2019-11-05 | $26.56M derived: sum of 2 quarters · filed 2019-11-05 | $38.21M 10-Q · filed 2019-11-05 | $50.36M derived: sum of 4 quarters · filed 2019-11-05 | ||||
| 2018-06-30 | $13.70M 10-Q · filed 2019-08-06 | $25.35M 10-Q · filed 2019-08-06 | $37.50M derived: sum of 3 quarters · filed 2019-08-06 | $58.93M derived: sum of 4 quarters · filed 2019-08-06 | ||||
| 2018-03-31 | $11.65M 10-Q · filed 2019-05-02 | $23.80M derived: sum of 2 quarters · filed 2019-05-02 | $45.23M derived: sum of 3 quarters · filed 2019-05-02 | $53.07M derived: sum of 4 quarters · filed 2019-05-02 | ||||
| 2017-12-31 | $12.15M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-05 | $33.58M derived: sum of 2 quarters · filed 2019-03-05 | $41.41M derived: sum of 3 quarters · filed 2019-03-05 | $47.22M 10-K · filed 2019-03-05 | ||||
| 2017-09-30 | $21.43M 10-Q · filed 2018-11-08 | $29.27M derived: sum of 2 quarters · filed 2018-11-08 | $35.07M 10-Q · filed 2018-11-08 | |||||
| 2017-06-30 | $7.83M 10-Q · filed 2018-08-06 | $13.64M 10-Q · filed 2018-08-06 | ||||||
| 2017-03-31 | $5.80M 10-Q · filed 2018-05-09 | |||||||
| 2016-12-31 | $14.25M 10-K · filed 2019-03-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |